Who is sponsoring NCT05478993?

NCT05478993 is sponsored by Peking University People's Hospital.

What drugs are being tested in NCT05478993?

Interventions in NCT05478993: SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone.

What condition does NCT05478993 study?

NCT05478993 studies Multiple Myeloma.

Is NCT05478993 still recruiting?

NCT05478993 is currently status unknown. Last updated 31 January 2024.

Last reviewed 2024-01-31 · How we verify

NCT05478993: SPODUMENE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement

Status unknown Phase 2 Last updated 31 January 2024

What this trial tests

Phase 2 trial testing SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone in Multiple Myeloma in 21 participants. Status unknown.

Timeline

12 October 2022

Primary endpoint
10 July 2024

10 July 2025

Quick facts

Lead sponsor	Peking University People's Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	12 October 2022
Primary completion	10 July 2024
Estimated completion	10 July 2025
Sites	2 locations across China

Drugs / interventions tested

SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Peking University People's Hospital

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, open-label, multicenter, exploratory study initiated by investigator to evaluate the efficacy and safety of Selinexor (S) combined with pomalidomide (P) and dexamethasone (D) in the treatment of multiple myeloma with CNS involvement.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Selinexor: Targeting a novel pathway in multiple myeloma.
Mo CC, Yee AJ, Midha S, Hartley-Brown MA, et al · · 2023 · cited 20× · PMID 37601856 · DOI 10.1002/jha2.709
Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma.
Abramson HN. · · 2023 · cited 12× · PMID 36768967 · DOI 10.3390/ijms24032645
Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?
Sokolova V, Gruber R, Pammer LM, Kocher F, et al · · 2024 · cited 1× · PMID 39729162 · DOI 10.1007/s11033-024-10169-5

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05478993 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 31 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05478993.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing